Bayesian Optimal Designs for Phase I Clinical Trials (Q3079157): Difference between revisions

From MaRDI portal
Set OpenAlex properties.
ReferenceBot (talk | contribs)
Changed an Item
 
Property / cites work
 
Property / cites work: Optimum Dose Levels when Males and Females Differ in Response / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian design for estimating the turning point of a quadratic regression / rank
 
Normal rank
Property / cites work
 
Property / cites work: The Equivalence of Constrained and Weighted Designs in Multiple Objective Design Problems / rank
 
Normal rank
Property / cites work
 
Property / cites work: A Random Walk Rule for Phase I Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: A Curve‐Free Method for Phase I Clinical Trials / rank
 
Normal rank
Property / cites work
 
Property / cites work: Sufficient conditions for extremum, penalty functions and regularity / rank
 
Normal rank
Property / cites work
 
Property / cites work: Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs / rank
 
Normal rank
Property / cites work
 
Property / cites work: Design of Experiment for Bioassay / rank
 
Normal rank
Property / cites work
 
Property / cites work: Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve / rank
 
Normal rank
Property / cites work
 
Property / cites work: Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q4768502 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Optimum Experimental Designs for Multinomial Logistic Models / rank
 
Normal rank

Latest revision as of 19:24, 3 July 2024

scientific article
Language Label Description Also known as
English
Bayesian Optimal Designs for Phase I Clinical Trials
scientific article

    Statements

    Bayesian Optimal Designs for Phase I Clinical Trials (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    1 March 2011
    0 references
    constrained optimal design
    0 references
    maximum tolerated dose
    0 references
    sequential design
    0 references

    Identifiers

    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references